ALB and Shock: The Albumin Replacement therapy In Septic Shock (ARISS) study will investigate whether maintenance of serum albumin levels of ≥3.0 g/dL with HAS for 28 days improves survival in patients with septic shock when compared with resuscitation and volume maintenance without albumin [215].